238 related articles for article (PubMed ID: 28700424)
21. Mutational and Immunophenotypic Profiling of a Series of 8 Tubo-ovarian Carcinosarcomas Revealed a Monoclonal Origin of the Disease.
Trento M; Munari G; Carraro V; Lanza C; Salmaso R; Pizzi S; Santoro L; Chiarelli S; Dal Santo L; Nardelli GB; Saccardi C; Nicoletto O; Baldoni A; Rugge M; Fassan M
Int J Gynecol Pathol; 2020 Jul; 39(4):305-312. PubMed ID: 31688243
[TBL] [Abstract][Full Text] [Related]
22. Uterine carcinosarcoma (malignant mixed Müllerian tumor): case report in a goat and literature review.
Cossic B; Hill JA; Cercone M; Southard T
J Vet Diagn Invest; 2018 Nov; 30(6):955-961. PubMed ID: 30345891
[TBL] [Abstract][Full Text] [Related]
23. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy.
Rottmann D; Snir OL; Wu X; Wong S; Hui P; Santin AD; Buza N
Mod Pathol; 2020 Jan; 33(1):118-127. PubMed ID: 31477811
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical survey of mismatch repair protein expression in uterine sarcomas and carcinosarcomas.
Hoang LN; Ali RH; Lau S; Gilks CB; Lee CH
Int J Gynecol Pathol; 2014 Sep; 33(5):483-91. PubMed ID: 25083964
[TBL] [Abstract][Full Text] [Related]
25. Pax8: a marker for carcinoma of Müllerian origin in serous effusions.
Tong GX; Devaraj K; Hamele-Bena D; Yu WM; Turk A; Chen X; Wright JD; Greenebaum E
Diagn Cytopathol; 2011 Aug; 39(8):567-74. PubMed ID: 20607683
[TBL] [Abstract][Full Text] [Related]
26. Sarcomatous Component in Uterine Carcinosarcomas Correlates With Advanced Stage and Poorer Prognosis.
Podoll MB; Moghadamfalahi M; Faber E; Bishop JA; Alatassi H
Int J Gynecol Pathol; 2018 Jan; 37(1):22-26. PubMed ID: 28319572
[TBL] [Abstract][Full Text] [Related]
27. Differential diagnosis between uterine carcinosarcoma versus carcinoma with sarcomatous metaplasia: an immunohistochemical and ultrastructural case study.
Raspollini MR; Taddei GL; Marchionni M; Bacci S; Romagnoli P
Ultrastruct Pathol; 2005; 29(2):149-55. PubMed ID: 16028671
[TBL] [Abstract][Full Text] [Related]
28. Expression of p27 and p53: comparative analysis of uterine carcinosarcoma and endometrial carcinoma.
Abargel A; Avinoach I; Kravtsov V; Boaz M; Glezerman M; Menczer J
Int J Gynecol Cancer; 2004; 14(2):354-9. PubMed ID: 15086737
[TBL] [Abstract][Full Text] [Related]
29. Carcinosarcoma of the uterus: immunohistochemical and genetic analysis of clonality of one case.
Watanabe M; Shimizu K; Kato H; Imai H; Nakano H; Sugawa M; Shiraishi T
Gynecol Oncol; 2001 Sep; 82(3):563-7. PubMed ID: 11520156
[TBL] [Abstract][Full Text] [Related]
30. SATB2 Expression Is Sensitive but Not Specific for Osteosarcomatous Components of Gynecologic Tract Carcinosarcomas: A Clinicopathologic Study of 60 Cases.
Sangoi AR; Kshirsagar M; Horvai AE; Roma AA
Int J Gynecol Pathol; 2017 Mar; 36(2):140-145. PubMed ID: 27294605
[TBL] [Abstract][Full Text] [Related]
31. Tissue polypeptide antigen production in a uterine carcinosarcoma cell line in a serum-free culture.
Emoto M; Iwasaki H; Kikuchi M; Shirakawa K
Gynecol Oncol; 1996 Mar; 60(3):443-9. PubMed ID: 8774655
[TBL] [Abstract][Full Text] [Related]
32. Characterization of type I collagen synthesis and maturation in uterine carcinosarcomas.
Kauppila S; Stenbäck F; Kacinski BM; Carcangiu ML; Risteli J; Risteli L
Cancer; 1999 Oct; 86(7):1299-306. PubMed ID: 10506717
[TBL] [Abstract][Full Text] [Related]
33. Carcinosarcoma (malignant mixed müllerian tumor) of the uterus with a rhabdoid tumor component. An immunohistochemical, ultrastructural, and immunoelectron microscopic case study.
Mount SL; Lee KR; Taatjes DJ
Am J Clin Pathol; 1995 Feb; 103(2):235-9. PubMed ID: 7856569
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients.
Iwasa Y; Haga H; Konishi I; Kobashi Y; Higuchi K; Katsuyama E; Minamiguchi S; Yamabe H
Cancer; 1998 Feb; 82(3):512-9. PubMed ID: 9452269
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus.
Winter WE; Seidman JD; Krivak TC; Chauhan S; Carlson JW; Rose GS; Birrer MJ
Gynecol Oncol; 2003 Oct; 91(1):3-8. PubMed ID: 14529656
[TBL] [Abstract][Full Text] [Related]
36. Histologic Appearance and Immunohistochemistry of DNA Mismatch Repair Protein and p53 in Endometrial Carcinosarcoma: Impact on Prognosis and Insights Into Tumorigenesis.
Saijo M; Nakamura K; Ida N; Nasu A; Yoshino T; Masuyama H; Yanai H
Am J Surg Pathol; 2019 Nov; 43(11):1493-1500. PubMed ID: 31478942
[TBL] [Abstract][Full Text] [Related]
37. Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis.
Jin Z; Ogata S; Tamura G; Katayama Y; Fukase M; Yajima M; Motoyama T
Int J Gynecol Pathol; 2003 Oct; 22(4):368-73. PubMed ID: 14501818
[TBL] [Abstract][Full Text] [Related]
38. Loss of p16 in recurrent malignant mixed müllerian tumors of the uterus.
Robinson-Bennett B; Belch RZ; Han AC
Int J Gynecol Cancer; 2006; 16(3):1354-7. PubMed ID: 16803529
[TBL] [Abstract][Full Text] [Related]
39. Carcinoma (malignant mixed müllerian [mesodermal] tumor) of the uterus and ovary. Correlation of clinical, pathologic, and immunohistochemical features in 29 cases.
Costa MJ; Khan R; Judd R
Arch Pathol Lab Med; 1991 Jun; 115(6):583-90. PubMed ID: 1710102
[TBL] [Abstract][Full Text] [Related]
40. Carcinosarcoma of the uterus with melanocytic differentiation.
Kajo K; Zubor P; Spacek J; Ryska A
Pathol Res Pract; 2007; 203(10):753-8. PubMed ID: 17656038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
